Cellceutix Corp. (CTIX.OB) Monday said it received Qualified Infectious Disease Product or QIDP designation from the U.S. Food and Drug Administration or FDA for Brilacidin as a new treatment for Acute Bacterial Skin and Skin Structure Infections or ABSSSI. The designation is part of the Generating Antibiotic Incentives Now or GAIN Act.
Cellceutix is planning for Phase 3 trial of Brilacidin for ABSSSI as it has completed a Phase 2b trial in September.
For comments and feedback contact: editorial@rttnews.com
Business News